Treatment of Advanced and Metastatic NSCLC: The Sky Is the Limit

Benjamin Levy, MD


September 30, 2022

Benjamin Levy, MD, recalls a memorable patient with advanced non–small cell lung cancer (NSCLC) whom he treated over a decade ago. The patient had already progressed on multiple lines of therapy and was included in a clinical trial testing an immunotherapy drug combined with another agent. To this day, the patient stays in contact with Dr Levy, who considers this patient's success a testament to science.

Dr Levy explains how the complexities of scientific advances have translated to better outcomes for patients with advanced NSCLC. For Dr Levy, the "sky is the limit" in how far the science can progress to provide highly personalized cancer treatments for patients with NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.